All posts by imreal

Industry: Healthcare

Genstar Capital Completes Acquisition of OEConnection Holdings LLC

Leave a comment


“We are thrilled to join forces with Genstar as we continue to work to expand the OEC footprint and our product and service offerings for customers across the globe,” said Chuck Rotuno, OEC Chairman & CEO.


CLEVELAND and SAN FRANCISCO (PRWEB)

OEConnection LLC (“OEC” or the “Company”), the leading global automotive technology provider for OEM distribution networks, and Genstar Capital (“Genstar”), today announced they have finalized a deal for Genstar to acquire a majority stake in OEC. This transaction was first announced on August 1, 2019. Current investors, Ford Motor Company and General Motors, will each retain their minority investments in the Company.

Financial terms of the transaction were not disclosed.

OEC was founded in 2000 as a partnership between several original equipment manufacturers (“OEMs”), including Ford and General Motors, to provide high-quality technology solutions to facilitate the sale of original equipment replacement parts between automakers and franchised dealers and their wholesale customers. Since its founding, the Company has expanded to also provide software and technology solutions in the data, supply chain and service segments of OEMs’ businesses. Today, OEC is a leading provider of software solutions and data to the original equipment parts industry and is one of the industry’s only end-to-end comprehensive platforms, serving more than 30,000 auto dealers globally, 36 global OEM brands and more than 135,000 global auto repairers.

“We are thrilled to join forces with Genstar as we continue to work to expand the OEC footprint and our product and service offerings for customers across the globe,” said Chuck Rotuno, OEC Chairman & CEO. “Genstar has an impressive track record of partnering with companies in the software sector to accelerate growth and transformational change.”

About OEC

OEC is the leading global automotive technology provider for OEM distribution networks. Its suite of ecommerce, pricing, supply chain, service, business intelligence, parts cataloging, data solutions, and services helps automakers and their dealer networks sell more OE parts in the collision, fleet, mechanical and retail segments, as well as dealers’ own service lanes. OEC serves more than 30,000 auto dealers globally, 36 global OEM brands and more than 135,000 global auto repairers. The company is headquartered in the greater Cleveland area at 4205 Highlander Parkway, Richfield, Ohio, USA, 44286. Additional information is available at http://www.oeconnection.com

About Genstar Capital

Genstar Capital (http://www.gencap.com) is a leading private equity firm that has been actively investing in high quality companies for over 30 years. Based in San Francisco, Genstar works in partnership with its management teams and its network of strategic advisors to transform its portfolio companies into industry-leading businesses. Genstar currently has approximately $17 billion of assets under management and targets investments focused on targeted segments of the financial services, healthcare, industrial technology and software industries.

Media Contacts

OEC:

Geo Money 330-523-1853

Geo.Money@OEConnection.com

Genstar:

Chris Tofalli

Chris Tofalli Public Relations, LLC 914-834-4334

Share article on social media or email:

Business: Executives

UNAIDS and ThoughtFocus Announce IoT Partnership

Leave a comment



NEW YORK (PRWEB)

The Joint United Nations Programme on HIV/AIDS (UNAIDS), through the Health Innovation Exchange, today announced its partnership with ThoughtFocus, a leading technology services company, to establish an Internet of Things (IoT) Center of Excellence. IoT has opened a world of possibilities in health. When connected to the internet, ordinary medical devices can collect invaluable additional data, give extra insight into symptoms and trends, enable remote care, and generally give patients more control over their lives and quality of treatment.

The center will work with health care agencies, manufacturers, Governments, NGOs, communities and other relevant stakeholders to promote the use of IoT in public health and contribute towards establishing shared practices and standards.

The Health Innovation Exchange aims to bridge the disconnect that exists between innovators and implementers in health to fast-track progress to reach Universal Health Coverage (UHC) and other health related Sustainable Development Goals (SDG).

ThoughtFocus, a recognized IoT innovator will make its platform code base available without charge to the Center of Excellence to develop new innovative health solutions. The ThoughtFocus IoT platform is optimized to serve as an affordable, reliable and efficient platform to build and extend IoT solutions. The IoT platform has achieved success in solutions for transportation and logistics, manufacturing and utilities.

Rajiv Goyal, Executive Vice President at ThoughtFocus, said, “ThoughtFocus is committed to making a positive impact on the world and communities we serve. Our partnership with UNAIDS will help others in the Health Innovation Exchange accelerate innovations that address critical health issues of the world.” He highlighted that, “ThoughtFocus worked with the Bill and Melinda Gates foundation and Kohler to build eco-friendly sustainable toilets. We also provided IoT solutions for dairy farmers in rural India. We have demonstrated how IoT improves the lives of tens of thousands of economically challenged individuals and opens up new opportunities for them.”

“Realtime data is critical for transforming healthcare and we are really looking forward to exploiting the potential of IoT and connected devices to improve access and secure supply chain solutions,” said Pradeep Kakkattil, Director, Office of Innovation at UNAIDS, who also expressed his organization’s delight that ThoughtFocus will be joining the Health Innovation Exchange.

About UNAIDS

UNAIDS is a model for United Nations reform and is the only co-sponsored Joint Program in the United Nations system. The co-sponsors include UNHCR, UNICEF, WFP, UNDP, UNFPA, UNODOC, UN Women, ILO, UNESCO, WHO and The World Bank. Since its beginning in 1996, UNAIDS has led and inspired global, regional and local leadership, innovation and partnership. UNAIDS advocacy and leadership has resulted in putting 22 million people living with HIV on life saving treatment in the last 15 years. UNAIDS provides the strategic direction, advocacy, coordination and technical support needed to catalyze and connect leadership from governments, private sector and communities to deliver lifesaving services.

About ThoughtFocus

ThoughtFocus is a privately held technology and services company serving large to middle-market clients in Financial Services, Manufacturing, Aerospace, Higher Education. Clients look to ThoughtFocus for innovative solutions in product engineering, knowledge process outsourcing and digital transformation. The company has over 1,900 employees globally and is one of the fastest growing technology services companies. ThoughtFocus is a technology partner and portfolio investment company of Blackstone, a leading private equity firm.

ThoughtFocus has its US offices in New York City, Milwaukee, Atlanta, Dallas and Irvine with delivery centers in India at Bengaluru, Mysuru, Gurgaon, Hyderabad and in the Philippines at Baguio City.

Image: (Left to Right)

Pradeep Kakkattil, Director, Office of Innovation at UNAIDS

Rajiv Goyal – Executive Vice President, ThoughtFocus

Gunilla Carlsson – Executive Director, UNAIDS

Suman Radhakrishna – Chief Executive Officer (CEO) ThoughtFocus

Shylesh Krishnan – Executive Vice President, ThoughtFocus

###

Share article on social media or email:

Health

BioFactura Awarded $67.4 Million Advanced Development Contract for its Smallpox Biodefense Therapeutic

Leave a comment


News Image

“We look forward to working with BARDA in this new chapter of product development as we bring an important defense to our citizens,” shares Dr. Darryl Sampey, President and CEO of BioFactura


FREDERICK, Md. (PRWEB)

BioFactura, Inc. today announced a contract awarded by the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $67.4 million for the advanced development of its Smallpox Biodefense Therapeutic as a potential medical countermeasure (MCM) for the treatment of smallpox. This product has the potential to fulfill an unmet need in preparedness for a second anti-viral therapeutic with a different mechanism of action to the current stockpile to guard against potential host resistance.

This contract for the development of the Smallpox Biodefense Therapeutic consists of a base phase, valued at approximately $9.5 million, and three option phases over a total of 5 years. Under the base period-of-performance, work will focus on the development of manufacturing processes for the drug components, final product formulation, analytical method development, stability studies and regulatory activities to support formal engagement with the FDA. In addition to the base, the contract also includes U.S. Government options that may be activated to support process optimization and clinical manufacturing, additional non-clinical development studies to support an Investigational New Drug filing, and a first-in-humans Phase 1 clinical study.

While smallpox was declared eradicated in 1980 by the World Health Organization after an extensive vaccination campaign, the threat of bioterrorism and/or inadvertent release remains. Although TPOXX® (Tecovirimat, SIGA Technologies, Inc.) received FDA approval for smallpox treatment in 2018, Variola Virus (VARV), the causative agent for smallpox infections in humans, can become resistant to treatment suggesting that the best medical countermeasure approach would utilize complementary therapeutics. To fill the need for additional treatment options, BioFactura, in partnership with BARDA, is advancing the development of its monoclonal antibody-based Smallpox Biodefense Therapeutic in a stepwise approach building upon years of early product research and development and a strong foundation of cell line, process, analytical and

manufacturing development experience and expertise.

Dr. Darryl Sampey, President and CEO of BioFactura, stated, “This advanced research and development contract award marks the culmination of decades of discovery and development work performed by our team, our partners at the National Institutes of Health and our principal government collaborator Dr. Jay Hooper at the U.S. Army Research Institute of Infectious Diseases. We look forward to working with BARDA in this new chapter of product development as we bring an important defense to our citizens.”

“This government contract for the development of a novel smallpox therapeutic countermeasure is the result of years of cutting edge biotechnology research, the perseverance of forward-thinking scientific entrepreneurs, the risk appetite of loyal investors, and the dedication of the Department of HHS/BARDA to maintain the safety and security of the United States population,” stated Dr. Jeffrey Hausfeld, BioFactura’s Chief Medical Officer and Chairman. “It is truly an evolving American success story and one which as a physician and Chairman of the Board of BioFactura, I am proud to be a part of.”

This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50119C00054.

About BioFactura, Inc.

BioFactura, Inc. (Frederick MD) develops and commercializes high-value biodefense medical countermeasures and biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast™ Biomanufacturing Platform, the optimal system for bringing these drugs to market with faster, lower cost, superior-quality manufacture. For over 15 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies.

Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases. http://www.biofactura.com

Share article on social media or email:

Industry: Healthcare

Kiran Mazumdar-Shaw Promises to Enable Universal Access to rh-Insulin by Reducing Prices to Less than 10 US cents /Day for LMICs

Leave a comment


At Biocon, we are guided by the conviction that a lifesaving product like insulin cannot be priced out of the reach of those that need it on an everyday basis, whether in advanced economies like the United States or in Africa, or anywhere else on the planet.


NEW YORK (PRWEB)

Ms Kiran Mazumdar-Shaw, Philanthropist and Founder of Biocon, today, announced her personal commitment towards enabling universal access to high quality insulin by offering recombinant human Insulin (rh-Insulin) at less than 10 US cents / day in low and middle-income countries (LMICs). These countries, which form most of the world, contribute to 80% of the global disease burden.

The announcement was made at an United Nations General Assembly (UNGA) side meeting on innovation and universal health access convened by UNAIDS Health Innovation Exchange, in the presence of the President of Ethiopia, the First Lady of Namibia, Health Ministers from Botswana and Malawi, and representatives from the Private Sector and Development Agencies. The forum on ‘Accelerating Innovations and Investments for Access to Healthcare’ was co-sponsored by UNAIDS and the Center for Global Health and Development.

Biocon Biologics’ recombinant human insulin has been developed using the scientific expertise and world class R&D and manufacturing facilities that have allowed it to bring multiple biosimilar medicines to the US and Europe. The Company is committed to use its science, scale and expertise to shift the access paradigm for patients in need of insulins. Biocon is a leading global insulins player with over 15 years of experience in addressing the needs of patients with diabetes, having provided over 2 billion doses of human insulin worldwide, thus far.

The announcement by Ms Kiran Mazumdar-Shaw is guided by her conviction that a life-enabling product like insulin cannot be priced out of the reach of those that need it on an everyday basis, whether in the United States or in Africa.

Biocon’s Recombinant Human insulin offer of less than 10 US cents / day in LMICs is for vials sourced by the government directly from Biocon, assuming an insulin dosage of 40 IU per day.

Currently, the blended median patient prices in LMICs are US$ 9** per 10 ml vial translating to 36 US cents/ day. The current US list price in retail is over US$ 5*** / day.

Biocon, an India-based global biopharmaceuticals company is committed to affordability and access and will work with healthcare systems and payers worldwide to ensure that Insulin pricing is not a constraint to the well-being of individuals and of communities.

She also called upon insulin delivery devices manufacturers to join the movement towards ensuring affordable access to insulins by ensuring lower prices for the insulin pens and needles required to administer the drug.

Biocon Biologics is willing to work with governments to ensure ways to overcome price barriers, including through special pricing and setting up low-cost manufacturing facilities via public-private partnerships in order to address the huge cost burden borne by people with diabetes.

In high income regions like the US, Biocon believes it can make a dramatic impact on the current insulin pricing crisis if its ongoing discussions with the regulators allow the Company to scientifically bridge its clinical data to US reference product.

This will reduce clinical development costs and bring the product years earlier to patients who cannot afford insulin therapy.

Ms Kiran Mazumdar-Shaw is a healthcare visionary and philanthropist. Her vision is to enable universal access to high quality medical products, particularly to address the global chronic disease burden. She is a pioneer of India’s biotech industry and founder of the country’s leading biotechnology enterprise, Biocon. A thought leader and a global influencer, she has been ranked among ‘World’s 25 Most Influential People in Biopharma’ by Fierce Biotech. She was No. 1 in the Business Captains category on the ‘Medicine Maker Power List’ 2018, an index of the 100 most influential people across the globe in the field of medicine, where she has been among the Top 10 continuously since 2015.

She is a full-term member of the MIT Corporation, the board of trustees of the Massachusetts Institute of Technology (MIT), and member of the National Academy of Engineering, US. She is on the board of directors of the US-India Business Council (USIBC) and has previously served as a member of the board of trustees of the US Pharmacopeial Convention (USP). She has been conferred with the Advancing Women in Science and Medicine Award for Excellence by the Feinstein Institute for Medical Research, US and Othmer Gold Medal by the Chemical Heritage Foundation, US.

Biocon Limited, publicly listed in 2004, in India is a fully-integrated, innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases, benefitting a billion lives.

Biocon Biologics is its wholly owned subsidiary engaged in providing affordable access to high quality biosimilars to patients across the globe. It is driven by its vision to transform patients’ lives across the globe through innovative and inclusive healthcare solutions. Biocon’s rh-Insulin and Insulin Glargine products are already benefiting people with diabetes in many emerging and developed markets. In multiple countries like Mexico and Malaysia, nearly all insulin-requiring diabetics take Biocon’s insulins. Its rh-Insulin is registered in over 40 countries worldwide.

The Company is serving patients in U.S., EU, Japan, Latin America, Africa, Middle East and Turkey and the Asia-Pacific regions through its high quality biosimilars for diabetes and cancer. Biocon’s large scale, state-of-the-art bio-manufacturing facilities are qualified by various regulatory agencies from developed and emerging markets.

Note:

** Source: BMJ Global Health 2019: Insulin Prices Availability and affordability in 13 low income and middle income countries

*** Source:goodrx.com

###

Media Enquiries:

Seema Ahuja: seema.ahuja@biocon.com / +91 997 231 7792

Dr Bobby John: bj@aequitas.co / +1 202 902 9401

Share article on social media or email:

Business: Executives

Apex Catalyst Group, A Business Management Firm That Transforms Entrepreneurs Into Leaders Announces Rebranding and Launch Party

Leave a comment



DALLAS (PRWEB)

To celebrate this momentous occasion, Apex Catalyst Group is hosting a party at WeWork in Fort Worth, TX on October 1st, 2019 from 5:00-7:00PM CST. The party will also be streamed live over Facebook for those that want to join the party, right from their office.

“It is important for business owners to take time to celebrate their growth, accomplishments and milestones. I find myself reminding my clients of that frequently and it is only appropriate that I take this moment to celebrate the company’s achievements”, says Sandi Mitchell, CEO of Apex Catalyst Group. Sandi is a certified executive coach and EOS® Entrepreneurial Operating System Professional Implementer who specializes in creating inspired work environments, aligning teams to maximize potential, and building work ecosystems built on trust and clear communication.

Apex Catalyst Group has worked with small to medium-sized businesses and corporations globally, concentrating in the Dallas-Fort Worth area, for the past six years with a focus on establishing bold organizations unafraid to change. Prior to rebranding, APEX Leadership Mastery was managed solely by Sandi Mitchell, and has grown to include a team of business experts who specialize in HR, sales, operations, marketing and more. Supported by a hand-picked team of elite advisors, the new Apex Catalyst Group will guide entrepreneurs on a strategic roadmap towards intentional success.

In addition to the launch party happening on October 1st, 2019, the rebranding of Apex Catalyst Group includes a completely redesigned website, a social media marketing campaign on Facebook and LinkedIn, a revamped logo, graphics, and print materials.

Share article on social media or email:

Health

Five Consumer Safety Guidelines When Vaping from Integrated Healthcare Solutions

Leave a comment


https://www.prweb.com/

Legitimate CBD vaporizers are different from e-cigarettes and do not draw carcinogens into the body. Consumers should always check for a Certificate of Analysis (COA) on packaging.

While vaping options are vast, not all cartridges are alike. That’s why we’ve put together five general safety guidelines to help consumers find quality vaporizers and make sure they get the outcome they expect.


IRVINE, Calif. (PRWEB)

As a result of hundreds of lung disease cases linked to e-cigarettes and vaping, Integrated Healthcare Solutions Inc. (IHS), a leading innovator in cannabidiol (CBD) products, has released new guidelines to help consumers choose safe, legal and effective CBD vaporizers.

According to Dorian Knape, CEO of woman-owned IHS, many of the cases stem from products that contain THC, nicotine and vitamin E acetate as well as impurities, so consumers should do their research before vaping.

“While vaping options are vast, not all cartridges are alike,” said Knape. “Consumers can take a few simple steps to make an informed buying decision. That’s why we’ve put together five general safety guidelines to help consumers find quality vaporizers and make sure they get the outcome they expect.”

1) Choose a Vaporizer Instead of an E-cigarette – Vaporizing is different from an e-cigarette and does not draw carcinogens into the body. Many e-cigarettes contain propylene glycol (PEG) and nicotine-flavored juices, which can be harmful, whereas Urban Bio vaporizers blend naturally derived floral terpene profiles with CBD.

2) Check the Certificate of Analysis (COA) – Consumers should be wary of products that lack a COA, which involves testing by an independent lab for THC, heavy metals, microbials, pesticides and other concentrates. Most reputable CBD manufacturers will feature a QR code on their product labels, which enables consumers to access the COA by lot number. The COA should note THC levels or ensure that contents are THC-free. Consumers should also make sure the COA indicates the product does not contain vitamin E acetate, solvents, microbes, pesticides and heavy metals. These additives can affect the body’s cells, causing inflammation of the lungs.

3) Investigate Cartridge Content and Brand Legitimacy – Avoid low-grade ingredients such as polypropylenes (PG) and PEG, vegetable glycerin (VG), nicotine and psychosomatic substances such as THC. Choose an established company and brand with address, web site and phone number clearly on product packaging.

4) Know Your Source – Don’t buy from street vendors or sources that can’t produce product documentation such as lot or batch numbers and current COAs, which indicate a track and trace process. Before choosing a vendor, consult your healthcare provider to determine safety.

5) Investigate the Power of Terpenes – Terpenes are natural aromatic compounds that produce a spectrum of scent associated with foods, perfumes, etc. Different strains of terpenes carry different therapeutic benefits. Established companies will clearly state the terpene profiles within their vape cartridges. This broadens the choice of effect sought by consumers and eliminates the need for nicotine and THC.

“At IHS, we’ve taken extensive steps to provide consumers with exceptionally pure vaporizers that are free of THC, nicotine, vitamin E acetate, heavy metals, microbes and other contaminants – and we back that up with third-party lab testing as demonstrated by our COAs,” said Knape. “Consumers can be confident when they vaporize with our Urban Bio Pure Inhalation Cannabidiol (PIC) Cartridges.”

Sourced from hemp extract, Urban Bio PIC Cartridges are high in antioxidants and available in nine organic terpene profiles. Each 400 MG, one-gram cartridge features a 510-threaded connection for universal compatibility. In addition to PIC Cartridges, the Urban Bio product line includes transdermal relief creams, rejuvenation skin creams, gummies, and water-soluble Oral Drops as well as Pure Nano Drops.

Integrated Healthcare Solutions Inc. is a woman-owned enterprise and leverages the collective talents of more than 130 employees to help people stay active and live pain free. The company has a 30-year track record in healthcare through its affiliates, including medical devices by VQ OrthoCare, exercise and rehabilitation by VQ ActionCare and certified-organic nutrition by Pucker Urban Farms. Today, IHS boasts the power of its proprietary nano-amplified CBD as a path to maintaining wellness, supported by a rigid quality assurance program and an insistence on product purity. The company markets its growing portfolio of CBD products and services directly to consumers, through premier retail and wholesale channels, and through established medical professionals.

For more information, visit http://www.ihsinc.com or call 949-794-3400.

Share article on social media or email:

Industry: Healthcare

Amada Senior Care of North Houston Ranks Perfect Score on Texas Survey for In-Home Senior Care

Leave a comment


“We started this journey with the simple goal of providing our seniors with safety and security in every environment,” said Troy Tice. “We will fight every day to make sure our seniors, veterans and anyone else who needs help has a way to find it.”


THE WOODLANDS, Texas (PRWEB)

Amada Senior Care of North Houston Earns Perfect Texas State Survey

100% Top Rating was Achieved in Official Review Conducted by Health and Human Services (HHS)

Amada Senior Care of North Houston was awarded the highest possible rating in a recent Health and Human Services survey. HHS surveys, including site visits, allow state employees to review a home care agency’s care practices and program documentation.

The HHS survey process helps to ensure that direct services provided by the visited agency are among the best in the senior care industry and are designed to help support the overall health of the agency’s clients. These results were certified for Amada Senior Care of North Houston, a licensed home care agency owned and operated by Amy and Troy Tice.

“This is the community I grew up in, my family lives in and we are committed to a mission of giving back,” said Troy Tice. “We started this journey with the simple goal of providing our seniors with safety and security in every environment. I am proud of our accomplishments, awards and reputation, but we are not done. We will fight every day to make sure our seniors, veterans and anyone else who needs help has a way to find it.”

State surveyors conduct an on-site review as part of the three-day HHS survey process. During the review, the survey team ensures the visited agency is in compliance with the regulations of the Texas Health and Human Services Commission.

Troy, Amy and the entire Amada North Houston team are dedicated to providing outstanding care that makes life safer, easier and more enjoyable for seniors in their community. The experienced and knowledgeable team members at Amada Senior Care North Houston stay involved with seniors’ needs throughout the entire care process, paying special attention to the unique situation of each and every client.

The Tices understand the importance of providing the services seniors truly need – from monitoring health and safety, to providing trained, compassionate caregivers, and to overseeing placement as needed – in order to serve as a valuable asset to seniors’ families and the entire Houston community. Call (832) 209-8846 to schedule a free care needs consultation with a senior advisor or fill out the request form online http://www.AmadaNorthHouston.com.

About Amada Senior Care

Founded in 2007, Amada is America’s trusted resource for caregiving and long-term care insurance claims advocacy. Learn about Amada’s goal to enrich the lives of seniors and their families at http://www.AmadaSeniorCare.com.

MEDIA CONTACT:

Jeremy Brooker

Director of Marketing – Amada Senior Care Corp.

(949) 544-1131    jeremy.b@amadaseniorcare.com

Share article on social media or email:

Business: Executives

Cayman Alternative Investment Summit Announces Appointment of Eurasia Group President & Founder Ian Bremmer to Conference Editorial Board

Leave a comment


Ian Bremmer CAIS Cayman Islands

Ian Bremmer was keynote speaker at CAIS in 2019

“As one of the most influential forums in the alternative investment industry, I’m delighted to be joining the CAIS20 Editorial Board and returning again as a keynote speaker.” – Ian Bremmer, Founder and President of Eurasia Group and GZERO Media.


GRAND CAYMAN, Cayman Islands (PRWEB)

The Cayman Alternative Investment Summit 2020 (“CAIS20”) today announced the appointment of Ian Bremmer, President and Founder of Eurasia Group and GZERO Media, to the conference’s editorial board. Bremmer will help to shape the agenda and speaker lineup around the 2020 conference theme: “Global. Digital. Responsible.”

Bremmer is a political scientist who helps business leaders, policy makers, and the general public make sense of the world around them. He is president and founder of Eurasia Group, the world’s leading political risk research and consulting firm, and GZERO Media, a company dedicated to providing intelligent and engaging coverage of international affairs. Bremmer is the author of 10 books, including the New York Times bestseller “Us vs Them: The Failure of Globalism” which examines the rise of populism across the world. He also serves as the Foreign Affairs Columnist and Editor at Large for Time magazine and teaches at Columbia University’s School of International and Public Affairs.

“Through this year’s ‘Global. Digital. Responsible.’ theme, we are continuing to expand the role CAIS plays in spearheading provocative conversations about the future of alternative investing,” said Chris Duggan, CAIS Conference Chair and Vice President of Business Development at Dart. “We are excited to add Ian Bremmer to the CAIS20 Editorial Board as his expertise on applying geopolitical risks to financial markets will help to drive meaningful discussions on and off stage at CAIS.”

Hosted by Dart Family Office, CAIS20 will take place at Kimpton Seafire Resort + Spa in the Cayman Islands on February 6-7, 2020. The seventh annual conference will convene more than 500 alternative investment managers, institutional investors, economists, policymakers and academics for keynote presentations and panel sessions that cover the latest themes influencing the alternative investing landscape, including globalization, geopolitical risk, artificial intelligence and trading, digitalization, climate, ESG, and responsible investing.

“As one of the most influential forums in the alternative investment industry, I’m delighted to be joining the CAIS20 Editorial Board and returning again as a keynote speaker,” said Ian Bremmer, Founder and President of Eurasia Group and GZERO Media. “At a time when societies are becoming more divided, CAIS20 provides a global platform for real debate on the future of alternative investing and the convergence of geopolitical risks.”

In addition to Bremmer, the CAIS20 Editorial Board includes Anthony Cowell, Partner & Head of Asset Management at KPMG (Cayman Islands); Nancy Davis, Managing Partner & CIO of Quadratic Capital Management; Jackie Doak, President of Business Development at Dart; Bill Kelly, CEO of CAIA Association; Jeff Klein, co-Chief Investment Officer of AIMS Aptitude at Goldman Sachs; Christina Qi, Founding Partner of Domeyard LP; Amin Rajan, CEO of CREATE-Research; Victoria Rock, Managing Director & Head of Alternatives Product at Legg Mason; Phil Schmitt, President & CEO of Summerwood Group; Valerie Sill, President, CEO & CIO of Dupont Capital Management; and, Kareen Stangherlin, Founding Partner of Zelos Capital Ltd.

Joining members of the editorial board on the stage at CAIS20 are early confirmed speakers including Leda Braga, CEO of Systematica Investments; Peter Branner, CIO of APG Asset Management; Wences Cezares, CEO of XAPO; Gerald Butts; Former Advisor to Prime Minister Justin Trudeau and Former President & CEO of World Wildlife Canada; Megan Greene, former Global Chief Economist at John Hancock Financial Services/Manulife Asset Management; David McKay, CEO of RBC; Rachel Pether, Senior Advisor at the Sovereign Wealth Fund Institute; and, John Studzinski, Managing Director and Vice Chairman of PIMCO.

Registration for CAIS20 is now open, with early bird prices available until December 31, 2019 at cais.ky. The event is free to attend for all qualified investors and media.

About the Cayman Alternative Investment Summit

The Cayman Alternative Investment Summit (CAIS) is an annual non-profit conference that convenes leading thinkers and decision makers from diverse segments of the global alternatives industry to discuss and debate the challenges and opportunities that will define the future of the industry. Hosted by Dart Family Office, CAIS is dedicated to supporting financial services both in the Cayman Islands and internationally. For more information, please visit cais.ky.

About Dart Family Office

Based in the Cayman Islands, the Dart Family Office manages Ken Dart’s global investment portfolio. Dart’s investments in Cayman range from real estate development, hospitality, retail, entertainment and finance. Guided by the vision of Ken Dart, Dart has developed more than $1.5 billion in mixed-use, residential, commercial, recreational, educational and hospitality properties throughout the Cayman Islands.

Share article on social media or email:

Health

Silicon Valley Hair Institute Announces Update to FUE Transplant Information for California Patients Seeking Hair Loss Restoration

Leave a comment


FUE transplant California

FUE transplant California

Bay Area locals have to remember that we are a bit spoiled in Silicon Valley. New technology is so normal here we forget that other people in the state of California are not so lucky!


SAN JOSE, Calif. (PRWEB)

Silicon Valley Hair Institute, the Bay Area leader in robotic hair transplantation at http://siliconvalleyhairinstitute.com/, is proud to announce a new post focused on information for California patients curious about Follicular Unit Extraction (FUE). The post explains that easy access to the newest advances in medicine nearby could be regular for Bay Area locals, but that easy access to medical breakthroughs might be more difficult for California residents living in other less technology-focused regions in the Golden State.

“Bay Area locals have to remember that we are a bit spoiled in Silicon Valley. New technology is so normal here we forget that other people in the state of California are not so lucky,” explained Miguel Canales, of Silicon Valley Hair Institute. “We care for patients who come from all over California just to get the innovative hair transplant technology Bay Area locals take for granted.”

California residents can review the Silicon Valley Hair Institute’s updated informational page on FUE (Follicular Unit Extraction) hair transplantation at http://siliconvalleyhairinstitute.com/fue-hair-transplant/. Men and women from outside the Bay Area can visit the institute to receive the best FUE transplantation surgery in the state. Interested persons can also learn about the ARTAS robotic system to help in hair loss surgery at http://siliconvalleyhairinstitute.com/artas/. California residents in search of the latest treatment for hair loss can reach to the clinic for a confidential, no-obligation consultation.

Patients Travel Far and Wide to Receive the Best FUE Transplant Surgery in California

Here is the background for this release. California’s leadership in new technology could give the impression all Californians have easy access. It may be simple to attain innovative medicine in larger cities around the state. State residents of rural, more remote areas, however, might need to travel further to gain access to new medical breakthroughs. Men suffering from baldness, or women searching for the latest hair thickening treatments, may be willing to drive several hours for the best FUE transplant in California.

The Bay Area clinic provides California-wide support for hair loss treatments. Many cities and towns throughout the state may not offer access to the latest in FUE robotic technology. People suffering from hair loss can travel for hours from Truckee, Sacramento, Livermore, or Pleasanton to find help at one of the best hair transplant specialists in the Bay Area.

A team of hair loss specialists supports patients from all over the state of California. Innovative treatments, including PRP Therapy and FUE robotic technology, can help out-of-towners find answers to thinning hair. For these reasons, Silicon Valley Hair Institute announces an update to the FUE transplant informational page.

About Silicon Valley Hair Institute

Silicon Valley Hair Institute (http://siliconvalleyhairinstitute.com/), under the leadership of top-rated California hair transplant surgeon Miguel Canales MD, is one of the best facilities offering San Francisco Bay Area hair transplants. Dr. Canales provides the full range of advanced hair transplant and hair restoration procedures for Bay Area residents, from San Francisco to San Mateo to Palo Alto. If one needs a hair transplant specialist, look no further than this Bay Area hair transplant center. Dr. Canales also performs female hair transplants for women and eyebrow restoration, thus offering the best hair transplant and robotic hair replacement options. Robotics include state-of-the-art ARTAS hair transplant technology. Call today to 650-551-1100 for a no-cost consultation, or for more information visit the website

Share article on social media or email:

Technology: Electronics

Cardinal Scale’s New SmartCan Digital Conversion System

Leave a comment


Cardinal Scale’s New SmartCan Digital Conversion System

Cardinal Scale’s New SmartCan Digital Conversion System

The NTEP-certified SmartCan features Fail-Safe mode which keeps your scale running in the event of a failed cell, SmartCal digital calibration adjustments, universal mounting brackets for easy field installation, and remote troubleshooting and scale monitoring through iSite software.


WEBB CITY, Mo. (PRWEB)

Digitize Your Scale with SmartCan

You can now digitize any existing analog scale using Cardinal Scale’s SmartCan analog-to-digital conversion system. SmartCan allows users to digitally monitor each individual load cell and identify cell failures quickly and effectively. The SmartCan system utilizes the advanced, internationally-standardized CAN (Controller Area Network) serial bus system to digitize the analog output signals from two or more independent load cells and send the data to the indicator.

The NTEP-certified SmartCan features Fail-Safe mode which keeps your scale running in the event of a failed cell, SmartCal digital calibration adjustments, universal mounting brackets for easy field installation, and remote troubleshooting and scale monitoring through iSite software. The compact enclosure size only requires minimal space. SmartCan is ideal for retrofitting existing analog scales or converting analog load cells to digital load cells. It may also be used with Guardian® hydraulic load cells.

SmartCan is housed in a compact, rugged weatherproof IP66 / NEMA 4 enclosure and doesn’t require cumbersome external power supplies, in most applications. The indicator software permits a maximum of 32 load cells that could be used in any combination with SmartCan (the homerun cable length, power supply, and sample rate may limit the number of load cells used, in some instances). There are seven different SmartCan boxes available for a wide range of configurations.

Versatile Applications

SmartCan may be used in a variety of different applications with new and existing truck scales, railroad scales, floor scales, bench scales, and batching systems.

Fail-Safe Mode

Cardinal Scale’s Fail-Safe feature with SmartCan allows the system to compensate for a failed load cell by mirroring the estimated value of the remaining cells to offset the failed cell. The Fail-Safe feature uses an algorithm to calculate an estimated value from the data of the remaining cells and creates a virtual load cell to replace the data from the down cell.

Troubleshoot through the Indicator

Cardinal Scale’s 225D Navigator and 825D Spectrum weight indicators easily interface with the SmartCan digital conversion system and provide onscreen diagnostics for load cell performance in real-time. The 825D makes corner and section trimming easier with its graphical, full-color display.

SmartCal®

The SmartCan system uses Cardinal Scale’s patented software algorithm called SmartCal® method of calibrating a scale. SmartCal® allows a quick calibration with no manual adjustments while the diagnostic software identifies real and potential system problems before they interrupt your weighing operations.

iSite Remote Monitoring

Cardinal Scale’s iSite is a cloud-based remote monitoring system for load cells connected to the SmartCan conversion box. Text and/or e-mail auto alerts can be sent for errors and warning events. Through secure online dealer access, scale diagnostics may be looked up remotely to quickly identify problems before they interrupt weighing operations.

NEST Toolkit Compatible

Authorized Cardinal Scale dealers may plug a NEST toolkit directly into the SmartCan box for additional onsite diagnostics. NEST allows you to view the diagnostics in your choice of millivolts or pounds. There are three display modes: signals display, minimum-maximum display, and signals minus zero reference display.

Onboard Diagnostics

The SmartCan system has onboard diagnostics that can be used by a technician to alert them of critical errors due to setup issues and hardware problems. The following diagnostics data is available and will be shown to the technician on the main weight screen of the 225D or 825D indicator:


  • Live (real time) Load Cell Weights

  • Minimum and Maximum Load Cell Weights

  • Deadload Shift (from original calibrated deadload)

  • Individual Load Cell Signal in Millivolts

  • DLC Controller Card Communication Error Count

  • iSite Status of Last Connection

Learn More:

https://cardinalscale.com/product/product-overview/Scale-Diagnostic-Tools/SmartCan-Digital-Conversion-System

Contact:

Cardinal Scale Manufacturing Co.

102 East Daugherty St.

Webb City, MO 64870

(800) 441-4237

cardinal@cardet.com

http://www.CardinalScale.com

Share article on social media or email: